---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-022600"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:44:21.058012+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ORIC reports Q3 2022 cash of $218M; pipeline studies on track for data in 1H 2023

## Summary
- Cash and investments of $218.0M as of Sep 30, 2022; expected to fund operations into 2H 2024.
- R&D expenses $14.7M (up from $12.9M); G&A $6.0M (up from $5.6M); IPR&D $5.0M milestone for ORIC-114.
- Initial Phase 1b data for ORIC-533, ORIC-114, and ORIC-944 expected in 1H 2023.
- FDA cleared US IND for ORIC-114; Phase 1b enrolling in South Korea with expansion to US.
- Preclinical data on ORIC-533 (CD73 inhibitor) to be presented at ASH Annual Meeting Dec 2022.

## SEC filing metadata
- accession: 0000950170-22-022600
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000095017022022600/0000950170-22-022600-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000095017022022600/oric-20221107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-022600
- JSON: https://secwatch.observer/filing/0000950170-22-022600.json
- Plain text: https://secwatch.observer/filing/0000950170-22-022600.txt

## Key facts
- Earnings Releases
  Oric Pharmaceuticals, Inc. reported financial results for the quarter ended September 30, 2022.
  - Period: the quarter ended September 30, 2022
  - Result: reported results
  source text: ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1796280/000095017022022600/0000950170-22-022600-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.